CalciMedica (NASDAQ:CALC) Earns Buy Rating from HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 329.18% from the stock’s previous close.

CALC has been the topic of several other research reports. Singular Research raised shares of CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th. Oppenheimer lifted their target price on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 10th.

CalciMedica Stock Down 0.4 %

Shares of CalciMedica stock traded down $0.02 during trading hours on Tuesday, hitting $4.66. The company’s stock had a trading volume of 223 shares, compared to its average volume of 28,742. The business has a fifty day moving average of $4.62 and a 200 day moving average of $4.80. The company has a market capitalization of $50.09 million, a PE ratio of -2.17 and a beta of 1.28. CalciMedica has a 1-year low of $1.75 and a 1-year high of $8.38.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. On average, sell-side analysts anticipate that CalciMedica will post -2.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Robert N. Wilson bought 8,443 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were acquired at an average price of $3.23 per share, with a total value of $27,270.89. Following the completion of the transaction, the director now owns 258,918 shares of the company’s stock, valued at approximately $836,305.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 53.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Meritage Portfolio Management grew its position in CalciMedica, Inc. (NASDAQ:CALC) by 360.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,000 shares of the company’s stock after purchasing an additional 36,000 shares during the period. Meritage Portfolio Management owned about 0.81% of CalciMedica worth $132,000 as of its most recent filing with the SEC.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.